ReviewCurrent topics in medicinal chemistry2016
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.
Review in Current topics in medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 7 syntheses or guidelines pooled it, 258 citations in OpenAlex.
- Systematic review and network meta-analysis of the efficacy, safety and tolerability of xanomeline plus trospium chloride compared with eight oral antipsychotics for the acute treatment of schizophrenia.Journal of comparative effectiveness research · 2026Pooled it
- Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review.CNS drugs · 2025Pooled it
- An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs.Neuroscience and biobehavioral reviews · 2023Pooled it
- Treatments for Social Interaction Impairment in Animal Models of Schizophrenia: A Critical Review and Meta-analysis.Schizophrenia bulletin · 2022Pooled it
- Comprehensive exploration of the genetic contribution of the dopaminergic and serotonergic pathways to psychiatric disorders.Translational psychiatry · 2022Pooled it
- Clinical and Structural Differences in Delusions Across Diagnoses: A Systematic Review.Frontiers in integrative neuroscience · 2021Pooled it
- Antipsychotics for Amphetamine Psychosis. A Systematic Review.Frontiers in psychiatry · 2019Pooled it
- Transition rates to schizophrenia and early intervention effectiveness in substance-induced and brief psychotic disorders: a randomized controlled trial.Scientific reports · 2025Trial
- A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study).Journal of psychopharmacology (Oxford, England) · 2025Trial
- MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Anticancer Effects of Fluphenazine Alone and in Combination with Cisplatin in Gastric Cancer Cells and a Mouse Xenograft Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
- RP-HPLC quantification and separation of isomeric bacosides and exploration of their anti-schizophrenic potential by network pharmacology.RSC advances · 2026Article
- Structure-Affinity Relationship Optimization of SYA16263 Yields New Ligands with Improved Receptor Affinity and Antipsychotic-Like Properties.ACS omega · 2026Article
- The Role of the Ketogenic Diet in Modulating Biochemical Pathophysiology in Psychiatric and Neurodegenerative Disorders.International journal of molecular sciences · 2026Review
- A structural overview of G-protein-coupled receptors in neurological disorders.Acta pharmacologica Sinica · 2026Review
- Dopaminergic tone inhibits spontaneous glutamate release and augments homeostatic synaptic plasticity.Molecular psychiatry · 2026Article
- Budget impact of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the United States.Journal of managed care & specialty pharmacy · 2026Article
- Gut microbiota: contributing to high CVD prevalence in people living with schizophrenia?European archives of psychiatry and clinical neuroscience · 2026Review
- Hospital-based management of predominant negative symptoms in schizophrenia: an observational study.CNS spectrums · 2026Observational
- Emerging non-DFrontiers in psychiatry · 2026Review
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approximately 1% of the world's population. This disease is associated with considerable morbidity placing a major financial burden on society. Antipsychotics have been the mainstay of the pharmacological treatment of schizophrenia for decades. The traditional typical and atypical antipsychotics demonstrate clinical efficacy in treating positive symptoms, such as hallucinations and delusions, while are largely ineffective and may worsen negative symptoms, such as blunted affect and social withdrawal, as well as cognitive function. The inability to treat these latter symptoms may contribute to social function impairment associated with schizophrenia. The dysfunction of multiple neurotransmitter systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway are unlikely to meet all the therapeutic needs of this heterogeneous disorder. Often, however, the unintentional engagement of multiple pharmacological targets or even the excessive engagement of intended pharmacological targets can lead to undesired consequences and poor tolerability. In this article, we will review marketed typical and atypical antipsychotics and new therapeutic agents targeting dopamine receptors and other neurotransmitters for the treatment of schizophrenia. Representative typical and atypical antipsychotic drugs and new investigational drug candidates will be systematically reviewed and compared by reviewing structure-activity relationships, pharmacokinetic properties, drug metabolism and safety, pharmacological properties, preclinical data in animal models, clinical outcomes and associated side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.